Prof Adrienne Flanagan

Photo

Personal Profile

Name: Adrienne Flanagan Email: a.flanagan@ucl.ac.uk
Title: Prof Tel:
Department: Research Department of Pathology Fax:
Position: Professor of Musculo- Skeletal Pathology Address: , , ,
Research Domain: Personalised Medicine Web Page:  

Profile

Research Description

Our research programme focuses on identifying the genetic alterations involved in the development and progression of bone and soft tissue tumours. Correlation of these abnormalities with the histopathology improves diagnostic accuracy, allows sub-classification of neoplastic disease and helps to predict therapy, and outcome / survival. This approach has allowed us identify the molecule, brachyury, in a rare neoplasm, chordoma, which is now employed universally in the diagnosis of this tumour. We have demonstrated that GNAS1 mutations commonly occur in myxomas (benign tumour) which helps distinguish this from other tumours which are malignant. The group has strong ties with The Wellcome Trust Sanger Centre where genome-wide analyses are being performed on chordoma. We also are collaborating with a group in the National Human Genome Research Institute, National Institituteof Health, Washington, USA. The research benefits from having access to one of the largest subspecialty orthopaedics referral centres in Europe, The Royal National Orthopaedic Hospital.

Research Activities

Genetics of Sarcoma

Education Description

Undergraduate: cancer – pathology; bone and joint disease. Postgraduate: Basic sciences MSc in Orthopaedics, FRCPath Oxford Pathology Course; Advanced Histopathology Course in the East of England Deanery; Thames Deanery Bone and Soft Tissue Teaching for SHOs and SpRs; SpR training in Bone and Soft Tissue, Leeds; World Association of Societies of Pathology and Laboratory Medicine (WASPaLM), Penang 2008 – International Update on bone tumours; Association of Societies of Pathology and Laboratory Medicine (WASPaLM), Update Chandigarh 2010 – International Update on soft tissue tumours; “Notable gene expression: brachyury, mutations.” National Institutes of Health (NIH) meeting, “The First and Second International Chordoma Research Workshop.” Invitation only meeting. Plenary lecture May 2007 & 2008. Molecular genetic events in fibro-osseous and osteoclast-rich lesions of the jaw. The 14th International Congress of Oral Pathology and Medicine. San Francisco. June 2008. Plenary lecture and Seminar. ‘Crucial molecular genetic events in chordoma – plenary lectury’ 43rd Annual Musculoskeletal Tumor Meeting of the Japanese Orthopaedic Association, Shinjuku, Tokyo, Japan, June 2010.

UCL Collaborators

External Collaborators

Publications

    2013

    • Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM (2013). Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.. Nat Genet, , - . doi:10.1038/ng.2814
    • Kenny SL, Patel K, Humphries A, Davis M, Flanagan AM, McCluggage WG (2013). Ovarian cellular fibroma harbouring an isocitrate dehydrogenase 1 (1DH1) mutation in a patient with Ollier disease: evidence for a causal relationship. HISTOPATHOLOGY, 62(4), 667 - 670. doi:10.1111/his.12054
    • Tirabosco R, Pillay N, Berisha F, Amary FM, Flanagan AM (2013). Aldoketoreductasis 1 B10 (AKR1B10) Expression in Tissues and Tumors Showing Notochordal Differentiation. A Role as a Neoplastic Biomarker and a Potential Therapeutic Target.
    • Tirabosco R, Pillay N, Berisha F, Amary FM, Flanagan AM (2013). Aldoketoreductasis 1 B10 (AKR1B10) Expression in Tissues and Tumors Showing Notochordal Differentiation. A Role as a Neoplastic Biomarker and a Potential Therapeutic Target.
    • Presneau N, Eskandarpour M, Shemais T, Henderson S, Halai D, Tirabosco R, Flanagan AM (2013). MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.. Br J Cancer, 108(4), 964 - 972. doi:10.1038/bjc.2012.518
    • Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, Barkauskas DA, Marina N, de Toledo SR, Petrilli AS, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter DJ, Malats N, Kogevinas M, Wacholder S, Troisi R, Helman L, Fraumeni JF, Yeager M, Hoover RN, Chanock SJ (2013). Genome-wide association study identifies two susceptibility loci for osteosarcoma.. Nat Genet, , - . doi:10.1038/ng.2645
    • Tirabosco R, Berisha F, Ye H, Halai D, Amary MF, Flanagan AM (2013). Assessment of MUC4 expression in primary bone tumours. HISTOPATHOLOGY, 63(1), 142 - 143. doi:10.1111/his.12134
    • Amary MF, Ye H, Berisha F, Tirabosco R, Presneau N, Flanagan AM (2013). Detection of USP6 gene rearrangement in nodular fasciitis: an important diagnostic tool. VIRCHOWS ARCHIV, 463(1), 97 - 98. doi:10.1007/s00428-013-1418-0
    • Guilhamon P, Eskandarpour M, Halai D, Wilson GA, Feber A, Teschendorff AE, Gomez V, Hergovich A, Tirabosco R, Fernanda Amary M, Baumhoer D, Jundt G, Ross MT, Flanagan AM, Beck S (2013). Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.. Nat Commun, 4, 2166 - . doi:10.1038/ncomms3166
    • van Oosterwijk JG, Meijer D, van Ruler MAJH, van den Akker BEWM, Oosting J, Krenacs T, Picci P, Flanagan AM, Liegl-Atzwanger B, Leithner A, Athanasou N, Daugaard S, Hogendoorn PCW, Bovee JVMG (2013). Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGF beta as Potential Targets. AMERICAN JOURNAL OF PATHOLOGY, 182(4), 1347 - 1356. doi:10.1016/j.ajpath.2012.12.036
    • Amary MF, O'Donnell P, Berisha F, Tirabosco R, Briggs T, Pollock R, Flanagan AM (2013). Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five cases.. Skeletal Radiol, 42(7), 947 - 957. doi:10.1007/s00256-013-1577-8
    • Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, da Cunha IW, Rodriguez-Viciana P, Cheng H, Tavares Guerreiro Fregnani JH, Reynolds P, Arceci RJ, Nicholson A, Triche TJ, Soares FA, Flanagan AM, Wang YZ, Strauss SJ, Sorensen PH (2013). ERBB4 confers metastatic capacity in Ewing sarcoma.. EMBO Mol Med, 5(7), 1019 - 1034. doi:10.1002/emmm.201202343
    • Forbes GE, Tirabosco R, Amary MF, Flanagan AM (2013). Employing MDM2 Amplification to Assess the Clinical Outcome in 92 Patients with Peripherally-Sited Atypical Lipomatous Tumours.
    • Brisson M, Kashima T, Delaney D, Tirabosco R, Clarke A, Cro S, Flanagan AM, O'Donnell P (2013). MRI characteristics of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma: retrospective comparison with histology and MDM2 gene amplification.. Skeletal Radiol, 42(5), 635 - 647. doi:10.1007/s00256-012-1517-z
    • Tarpey PS, Behjati S, Cooke SL, Van Loo P, Wedge DC, Pillay N, Marshall J, O'Meara S, Davies H, Nik-Zainal S, Beare D, Butler A, Gamble J, Hardy C, Hinton J, Jia MM, Jayakumar A, Jones D, Latimer C, Maddison M, Martin S, McLaren S, Menzies A, Mudie L, Raine K, Teague JW, Tubio JM, Halai D, Tirabosco R, Amary F, Campbell PJ, Stratton MR, Flanagan AM, Futreal PA (2013). Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma.. Nat Genet, , - . doi:10.1038/ng.2668

    2012

    • Ye H, Berisha F, Alorjani M, Eskandarpour M, Diss T, Tirabosco R, Flanagan AM, Amary M (2012). Detection of USP6 Gene Rearrangement in Nodular Fasciitis. An Important Diagnostic Tool.
    • Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R, Halai D, Berisha F, Flicek P, Stemple DL, Stern CD, Wardle FC, Flanagan AM (2012). An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.. J Pathol, 228(3), 274 - 285. doi:10.1002/path.4082
    • Kashima T, Halai D, Ye H, Hing SN, Delaney D, Pollock R, O'Donnell P, Tirabosco R, Flanagan AM (2012). Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor.. Mod Pathol, 25(10), 1384 - 1396. doi:10.1038/modpathol.2012.90
    • Duhamel LA, Ye H, Halai D, Idowu BD, Presneau N, Tirabosco R, Flanagan AM (2012). Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes.. Histopathology, 60(2), 357 - 359. doi:10.1111/j.1365-2559.2011.04023.x
    • Tirabosco R, Jacques T, Berisha F, Flanagan AM (2012). Assessment of integrase interactor 1 (INI-1) expression in primary tumours of bone. Histopathology, , - .

    2011

    • Pillay N, Fernanda MF, Berisha F, Tirabosco R, Flanagan AM (2011). P63 Does Not Regulate Brachyury in Chordomas and Osteosarcomas.
    • Pillay N, Amary FM, Berisha F, Tirabosco R, Flanagan AM (2011). P63 does not regulate brachyury expression in human chordomas and osteosarcomas.. Histopathology, 59(5), 1025 - 1027. doi:10.1111/j.1365-2559.2011.03973.x
    • Stephens PJ, Greenman CD, Fu BY, Yang FT, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia MM, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, Futreal PA, Campbell PJ (2011). Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development. CELL, 144(1), 27 - 40. doi:10.1016/j.cell.2010.11.055
    • Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM (2011). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.. J Pathol, 224(3), 334 - 343. doi:10.1002/path.2913
    • Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, Leithner A, Liegl B, Briggs TR, Bacsi K, Kindblom LG, Athanasou N, Amary MF, Hogendoorn PC, Tirabosco R, Flanagan AM (2011). The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.. J Pathol, 223(3), 336 - 346. doi:10.1002/path.2818
    • Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques TS, Kindblom LG, Brüderlein S, Möller P, Leithner A, Liegl B, Amary FM, Athanasou NN, Hogendoorn PC, Mertens F, Szuhai K, Flanagan AM (2011). Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study.. J Pathol, 223(3), 327 - 335. doi:10.1002/path.2816

    2010

    • Ye H, Shalaby A, Presneau N, Pillay N, Idowu B, Halai D, Tirabosco R, Jacques T, Mertens F, Szuhai K, Kindblom L, Hogendoom P, Flanagan AM (2010). Genetic Abnormalities of the Transcription Factor T (Brachyury) in Sporadic Chordomas.
    • Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques TS, Kindblom LG, Brüderlein S, Möller P, Leithner A, Liegl B, Amary FM, Athanasou NN, Hogendoorn PC, Mertens F, Szuhai K, Flanagan AM (2010). Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study.. J Pathol, , - . doi:10.1002/path.2816
    • Bousdras VA, Flanagan A, Bousdras KA, Vourvachis M, Newman L, Kalavrezos N (2010). Multiple-site osteosarcomas of the jaw in a single patient. A true case of metachronous lesion?. International Journal of Oral and Maxillofacial Surgery, 39(7), 733 - 736.
    • Tirabosco R, Arora R, Ye HT, Brunell C, Halai D, Flanagan AM (2010). Primary Myxoid Liposarcoma of the Ovary in an Adolescent Girl: A Case Report. INT J GYNECOL PATHOL, 29(3), 256 - 259. doi:10.1097/PGP.0b013e3181c03fc9
    • Tirabosco R, Flanagan AM (2010). INI-1 Expression in Cytokeratin-Positive Tumors of Bone.
    • Tirabosco R, Flanagan AM (2010). INI-1 Expression in Cytokeratin-Positive Tumors of Bone.
    • Tirabosco R, Galloway M, Bradford R, O'Donnell P, Flanagan AM (2010). Liposarcomatous differentiation in malignant peripheral nerve sheath tumor: A case report. PATHOL RES PRACT, 206(2), 138 - 142. doi:10.1016/j.prp.2009.04.005
    • McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, Mudie LJ, Hamalainen E, Stebbings LA, Andersson LC, Flanagan AM, Durbecq V, Ignatiadis M, Kallioniemi O, Heckman CA, Alitalo K, Edgren H, Futreal PA, Stratton MR, Campbell PJ (2010). Use of Cancer-Specific Genomic Rearrangements to Quantify Disease Burden in Plasma from Patients with Solid Tumors. GENE CHROMOSOME CANC, 49(11), 1062 - 1069. doi:10.1002/gcc.20815
    • Utting JC, Flanagan AM, Brandao-Burch A, Orriss IR, Arnett TR (2010). Hypoxia stimulates osteoclast formation from human peripheral blood.. Cell Biochem Funct, 28(5), 374 - 380. doi:10.1002/cbf.1660
    • Verbeke SL, Fletcher CD, Alberghini M, Daugaard S, Flanagan AM, Parratt T, Kroon HM, Hogendoorn PC, Bovée JV (2010). A reappraisal of hemangiopericytoma of bone; analysis of cases reclassified as synovial sarcoma and solitary fibrous tumor of bone.. Am J Surg Pathol, 34(6), 777 - 783. doi:10.1097/PAS.0b013e3181dbedf1
    • Flanagan AM, Delaney D, O'Donnell P (2010). Benefits of molecular pathology in the diagnosis of musculoskeletal disease : Part II of a two-part review: bone tumors and metabolic disorders.. Skeletal Radiol, 39(3), 213 - 224. doi:10.1007/s00256-009-0758-y
    • Flanagan AM, Delaney D, O'Donnell P (2010). The benefits of molecular pathology in the diagnosis of musculoskeletal disease. SKELETAL RADIOL, 39(2), 105 - 115. doi:10.1007/s00256-009-0759-x
    • Joseph L, Hing SN, Presneau N, O'Donnell P, Diss T, Idowu BD, Joseph S, Flanagan AM, Delaney D (2010). Familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3.. Skeletal Radiol, 39(1), 63 - 68. doi:10.1007/s00256-009-0808-5

    2009

    • Kashima TG, Halai DD, Tirabosco R, Hing S, Ye H, Flanagan AM (2009). An Audit of Lipomatous Neoplasms: Correlation with MDM2 Amplification by Fluorescence In Situ Hybridisation.
    • Kashima TG, Halai DD, Tirabosco R, Hing S, Ye H, Flanagan AM (2009). An Audit of Lipomatous Neoplasms: Correlation with MDM2 Amplification by Fluorescence In Situ Hybridisation.
    • Tirabosco R, Hing S, Carlstedx T, Flanagan AM (2009). Intraneural Perineurioma. FISH Assessment of the BCR Locus in 7 Cases.
    • Tirabosco R, Hing S, Carlstedt T, Flanagan AM (2009). Intraneural Perineurioma. FISH Assessment of the BCR Locus in 7 Cases.
    • Tirabosco R, Lang-Lazdunski L, Diss TC, Amary MFC, Rodriguez-Justo M, Landau D, Lorenzi W, Flanagan AM (2009). Clear cell sarcoma of the mediastinum. ANN DIAGN PATHOL, 13(3), 197 - 200. doi:10.1016/j.anndiagpath.2008.02.014
    • Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, Diss T, Tirabosco R, Flanagan AM (2009). Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.. Br J Cancer, 100(9), 1406 - 1414. doi:10.1038/sj.bjc.6605019
    • Delaney D, Diss TC, Presneau N, Hing S, Berisha F, Idowu BD, O'Donnell P, Skinner JA, Tirabosco R, Flanagan AM (2009). GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma.. Mod Pathol, 22(5), 718 - 724. doi:10.1038/modpathol.2009.32
    • Shalaby AA, Presneau N, Idowu BD, Thompson L, Briggs TR, Tirabosco R, Diss TC, Flanagan AM (2009). Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.. Mod Pathol, 22(8), 996 - 1005. doi:10.1038/modpathol.2009.63

    2008

    • Idowu BD, Thomas G, Frow R, Diss TC, Flanagan AM (2008). Mutations in SH3BP2, the cherubism gene, were not detected in central or peripheral giant cell tumours of the jaw.. Br J Oral Maxillofac Surg, 46(3), 229 - 230. doi:10.1016/j.bjoms.2007.04.014
    • Parrinello S, Noon LA, Harrisingh MC, Wingfield Digby P, Echave P, Cremona CA, Rosenberg LH, Flanagan AM, Parada LF, Lloyd AC (2008). NF1 loss disrupts Schwann cell-axonal interactions: a novel role for semaphorin 4F.. Genes and Development, 22(23), 3335 - 3348.
    • Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, De Maglio G, den Bakker MA, Di Francesco L, Kalil RK, Athanasou NA, O'Donnell P, McCarthy EF, Flanagan AM (2008). Brachyury expression in extra-axial skeletal and soft tissue chordomas: A marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. AM J SURG PATHOL, 32(4), 572 - 580.
    • Diss TC, Idowu BD, Hing SN, Delaney DW, Flanagan AM (2008). Improvements to GNAS1 Mutation Detection by COLD-PCR and Mutation Specific Restriction Enzyme Digestion Confirm an Association Between Fibrous Dysplasia and Intramuscular Myxoma at the Genetic Level.

    2007

    • Amary M, Idowu B, Islam L, Bousdras K, Pauwels P, Meulemans E, Diss T, Flanagan A (2007). Detection of B-Catenin Gene Mutations in Paraffin-Embedded Sporadic Desmoid-Type Fibromatosis by Mutation-Specific Restriction Enzyme Digestion (MSRED): An Ancillary Diagnostic Tool.
    • Harish S, O'Donnell P, Briggs TWR, Saifuddin A, Flanagan AM (2007). Myopericytoma in Kager's fat pad. SKELETAL RADIOL, 36(2), 165 - 169. doi:10.1007/s00256-006-0108-2
    • Bousdras K, O'Donnell P, Vujovic S, Henderson S, Boshoff C, Flanagan AM (2007). Chondroblastomas but not chondromyxoid fibromas express cytokeratins: an unusual presentation of a chondroblastoma in the metaphyseal cortex of the tibia. HISTOPATHOLOGY, 51(3), 414 - 416. doi:10.1111/j.1365-2559.2007.02777.x
    • Idowu BD, Mangion J, Gale RE, Flanagan AM (2007). Genetic mutations in the ras/raf/mapkinase pathway results in cherubism.
    • Idowu BD, Mangion J, Gale RE, Flanagan AM (2007). SH3BP2, PTPN11 and NF1 mutations resulting in the cherubism phenotype.
    • Vujovic S, Henderson SR, Flanagan AM, Clements MO (2007). Inhibition of gamma-secretases alters both proliferation and differentiation of mesenchymal stem cells.. Cell Prolif, 40(2), 185 - 195. doi:10.1111/j.1365-2184.2007.00426.x
    • Amary MFC, Idowu B, Islam L, Bousdras K, Pauwels P, Meulemans E, Diss TC, Flanagan AM (2007). Detection of b-catenin gene mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): An ancillary diagnostic tool.
    • O Donnell P, Tirabosco R, Vujovic S, Bartlett W, Briggs TWR, Henderson S, Boshoff C, Flanagan AM (2007). Diagnosing an extra-axial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation. Skeletal radiology, 36, 59 - 65.
    • Idowu BD, Al-Adnani M, O'Donnell P, Yu L, Odell E, Diss T, Gale RE, Flanagan AM (2007). A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone.. Histopathology, 50(6), 691 - 704.
    • Amary MFC, Diss TC, Flanagan AM (2007). Molecular characterization of a novel variant of a SYT-SSX1 fusion transcript in synovial sarcoma. HISTOPATHOLOGY, 51(4), 559 - 561. doi:10.1111/j.1365-2559.2007.02812.x
    • Fernanda M, Amary C, Pauwels P, Meulemans E, Roemen GM, Islam L, Idowu B, Bousdras K, Diss TC, O'Donnell P, Flanagan AM (2007). Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): An ancillary diagnostic tool. AM J SURG PATHOL, 31(9), 1299 - 1309.
    • Amary MFC, Berisha F, Bernardi FD, Herbert A, James M, Reis JS, Fisher C, Nicholson AG, Tirabosco R, Diss TC, Flanagan AM (2007). Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. MODERN PATHOL, 20(4), 482 - 496. doi:10.1038/modpathol.3800761
    • Amary MFC, Berisha F, Bernardi FDC, Reis-Filho JS, Diss TC, Flanagan AM (2007). Analysis of 134 formalin-fixed paraffin-em bedded synovial sarcomas by conventional RT-PCR, real time RT-PCR and dual colour FISH.
    • Amary MFC, Berisha F, Bernardi FDC, JS R-F, Diss TC, Flanagan AM (2007). Analysis of 134 Formalin-Fixed Paraffin-Embedded Synovial Sarcomas by Conventional RT-PCR, Real Time RT-PCR and Dual Colour FISH.
    • Tirabosco R, Diss TC, Bousdras K, Flanagan AM (2007). Molecular diagnosis of primitive neuro-ectodermal tumor/Ewing sarcoma (PNET/ES): Comparision of RT-PCR and FISH. A study of 104 cases.
    • Tirabosco R, Diss TC, Bousdras K, Flanagan AM (2007). Molecular diagnosis of primitive neuro-ectodermal Tumor/Ewing sarcoma (PNET/ES): Comparision of RT-PCR and FISH. A study of 104 cases.

    2006

    • Amary MFC, Lam L, Bernardi FDC, Michelagnoli M, Berisha F, Diss T, Flanagan AM (2006). SYT-SSX fusion transcript can be detected in a very high proportion of formalin-fixed paraffin-embedded synovial sarcomas using conventional, real-time RT-PCR and FISH.
    • Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, Boshoff C, Flanagan AM (2006). Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. The Journal of pathology, 209, 157 - 165.
    • Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan AM, Teague J, Wooster R, Futreal PA, Stratton MR (2006). COSMIC 2005. British Journal of Cancer, 94(2), 310 - 322.
    • Harish S, Hughes RJ, Saifuddin A, Flanagan AM (2006). Image-guided percutaneous biopsy of intramedullary lytic bone lesions: utility of aspirated blood clots. European Radiology, 16(9), 2120 - 2125.
    • O'Donnell P, Diss TC, Whelan J, Flanagan AM (2006). Synovial sarcoma with radiological appearances of primitive neuroectodermal tumour/Ewing sarcoma: differentiation by molecular genetic studies. Skeletal Radiology, 35(4), 345 - 350.
    • O'Donnell P, Diss TC, Whelan J, Flanagan AM (2006). Synovial sarcoma with radiological appearances of primitive neuroectodermal tumour/Ewing sarcoma: differentiation by molecular genetic studies. SKELETAL RADIOL, 35(4), 233 - 239. doi:10.1007/s00256-005-0006-z
    • Lam L, Berisha F, Diss TC, Flanagan AM (2006). Formalin-fixed paraffin-embedded material is a reliable source of RNA for molecular genetic analysis provided small fragments are targeted.
    • Islam L, Amary MF, Idowu B, Diss T, Flanagan AM (2006). Frequent detection of beta-catenin gene mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion.
    • Etessami N, Lam L, Berisha F, Flanagan AM, Diss TC (2006). Improved detection of FUS-CHOP fusion transcript in myxoid liposarcoma using real-time RT-PCR.
    • Vujovic S, Tiraboco R, Henderson S, Boschoff C, Flanagan AM (2006). Microarray analysis of mesenchymal tumours identifies brachyury, a novel biomarker for chordomas.
    • Gooding CR, Bartlett W, Bentley G, Skinner JA, Carrington R, Flanagan A (2006). A prospective, ranomised study comparing two techniques of autologous chondrocyte implantation for osteochondral defects in the knee: Periosteum covered versus type I/III collagen covered.. Knee, 13(3), 203 - 210.
    • Krishnan SP, Skinner JA, Carrington RW, Flanagan AM, Briggs TW, Bentley G (2006). Collagen-covered autologous chondrocyte implantation for osteochondritis dissecans of the knee: TWO- TO SEVEN-YEAR RESULTS.. Journal of Bone and Joint Surgery - Series B, 88(2), 203 - 205.
    • Gupta A, Saifuddin A, Briggs TW, Flanagan AM (2006). Subperiosteal hemangioendothelioma of the femur. Skeletal Radiology, 35(10), 793 - 796.
    • Krishnan SP, Skinner JA, Bartlett W, Carrington RW, Flanagan AM, Briggs TW, Bentley G (2006). Who is the ideal candidate for autologous chondrocyte implantation?. Journal of Bone and Joint Surgery - Series B, 88(1), 61 - 64.

    2005

    • Al-Adnani M, Cannon SR, Flanagan AM (2005). Chordomas do not express CD10 and renal cell carcinoma (RCC) antigen: an immunohistochemical study.. Histopathology, 47(5), 535 - 537.
    • Lam L, Diss TC, Berisha F, Idowu BD, Gale RE, Flanagan AM (2005). Differentiation between clear cell sarcoma and malignant melanoma using a molecular approach.
    • Diss TC, Berisha F, Lam L, Flanagan AM (2005). Detection of Ewing and synovial sarcoma fusion transcripts using conventional and real-time PCR.
    • Diss TC, Lam L, Berisha F, Flanagan AM (2005). Detection of Ewing and synovial sarcoma fusion transcripts using conventional and real-time RT-PCR.
    • Al-Adnani M, Idowu B, Yu L, Diss TC, Lam L, Gale RE, O'Dell E, Flanagan AM (2005). Detection of a new mutation in fibrous dysplasia using a modified site directed mutagenesis methodology.
    • Stubbs SA, Hardy K, Da Silva-Buttkus P, Stark J, Webber LJ, Flanagan AM, Themmen AP, Visser JA, Groome NP, Franks S (2005). Anti-mullerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries.. Journal of Clinical Endocrinology and Metabolism, 90(10), 5536 - 5543.
    • Diss TC, Lam L, Berisha F, Flanagan AM (2005). A real-time RT-PCR method for detection of EWS/ATF1 fusion transcripts in clear cell sarcoma using paraffin-embedded material.
    • Nicholls BM, Bredius RG, Hamdy NA, Gerritsen EJ, Lankester AC, Hogendoorn PC, Nesbitt SA, Horton MA, Flanagan AM (2005). Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor.. Journal of Bone and Mineral Research, 20(12), 2264 - 2270.
    • Al-Adnani M, Idowu B, Yu T, Diss TC, Gale RE, O'Dell E, Flanagan AM (2005). A simple and reliable method for the molecular diagnosis of fibrous dysplasia.
    • Nicholls BM, Bredius RG, Hamdy NA, Gerritsen EJ, Lankester AC, Hogendoorn PC, Nesbitt SA, Horton MA, Flanagan AM (2005). Limited rescue of osteoclast-poor osteopetrosis following successful engraftment by cord blood from an unrelated donor. Journal of Bone and Mineral Research, 20(12), 2264 - 2270.
    • Diss TC, Berisha F, Lam L, Flanagan AM (2005). Detection of Ewing and synovial sarcoma fusion transcripts using conventional and real-time PCR.
    • Stephens P, Edkins S, Davies H, Greeman C, Cox C, Hunter C, Bignell G, Teague J, Smith R, Stevens C, O'Meara S, Parker A, Tarpey P, Avis T, Barthorpe A, Brackenbury L, Buck G, Butler A, Clement J, Cole J, Dicks E, Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Shepherd R, Small A, Solomon H, Stephens Y, Tofts C, Varian J, Webb A, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LH, Malkowicz B, Pierotti MA, Teh B, Yuen ST, Nicolson AG, Lakhani S, Easton DF, Weber BL, Stratton MR, Futreal PA, Wooster R (2005). A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer.. Nature Genetics, 37(6), 590 - 592. doi:10.1038/ng1571
    • Henderson SR, Guiliano D, Presneau N, McLean S, Frow R, Vujovic S, Anderson J, Sebire N, Whelan J, Athanasou N, others (2005). A molecular map of mesenchymal tumors. Genome biology, 6, 76 - 76.
    • Steward CG, Blair A, Moppett J, Clarke E, Virgo P, Lankester A, Burger SR, Sauer MG, Flanagan AM, Pamphilon DH, Orchard PJ (2005). High peripheral blood progenitor cell counts enable autologous backup before stem cell transplantation for malignant infantile osteopetrosis.. Biology of Blood and Marrow Transplantation, 11(2), 115 - 121.
    • Bartlett W, Skinner JA, Gooding CR, Carrington RW, Flanagan AM, Briggs TW, Bentley G (2005). Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee: a prospective, randomised study.. Journal of Bone and Joint Surgery - Series B, 87(5), 640 - 645.
    • Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, Parker A, O'Meara S, Avis T, Barthorpe S, Brackenbury L, Buck G, Clements J, Cole J, Dicks E, Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Shepherd R, Small A, Solomon H, Stephens Y, Tofts C, Varian J, Webb A, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LH, Malkowicz B, Pierotti MA, Teh BT, Yuen ST, Lakhani SR, Easton DF, Weber BL, Goldstraw P, Nicholson AG, Wooster R, Stratton MR, Futreal PA (2005). Somatic mutations of the protein kinase gene family in human lung cancer.. Cancer Research, 65(17), 7591 - 7595.

    2004

    • Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Oarker A, Barthope A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Stepherd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Knowles M, Leung SY, Louis DN, Looijenga LH, Malkowicz B, Pierotti MA, Teh B, Chenevix-Trench G, Weber BL, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futreal PA, Wooster R, Stratton MR (2004). Lung Cancer: intragenic ERBB2 kinase mutations in tumours.. Nature, 30(431), 525 - 526. doi:10.1038/431525b
    • Nicholls BM, Bredius RG, Nesbitt SA, Horton MA, Flanagan AM (2004). LITTLE EVIDENCE OF RESCUE OF OSTEOCLAST-POOR OSTEOPETROSIS FOLLOWING 'SUCCESSFUL ENGRAFTMENT' BY CORD BLOOD FROM AN UNRELATED DONOR. CALCIFIED TISSUE INT, 74, S64 - S64.
    • Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan FG, Hamoudi RA, Diss T, Warren B, Al Adnani M, De Goeij AP, Krausz T, Flanagan AM (2004). In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. Journal of Pathology, 202(3), 336 - 340.
    • Green RA, Cannon SR, Flanagan AM (2004). Chondroid lipoma: correlation of imaging findings and histopathology oc an unusual benign lesion.. Skeletal Radiology, 33(11), 670 - 673.
    • Nicholls BM, Bredius R, Nesbitt SA, Horton MA, Flanagan AM (2004). Limited evidence of rescue of osteoclast-poor osteopetrosis following successful engraftment by cord blood from an unrelated donor.

    2003

    • Sieben NLG, Kolkman-Uljee SM, Flanagan AM, Le Cessie S, Cleton-Jansen AM, Cornelissa CJ, Fleuren GJ (2003). Molecular genetic evidence for monolonal origin of bilateral serous ovarian borderline tumours and implants. American Journal of Pathology, 162, 1095 - 1101.
    • Sieben NLG, Kolkman-Uljee SM, Flanagan AM, le Cessie S, Cleton-Jansen AM, Cornelisse CJ, Fleuren GJ (2003). Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors. AM J PATHOL, 162(4), 1095 - 1101.
    • Horton MA, Massey HM, Rosenberg N, Nicholls B, Seligsohn U, Flanagan AM (2003). Upregulation of osteoclast alpha2beta1 integrin compensates for lack of alphavbeta3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia. British Journal of Haematology, 122(6), 950 - 957.
    • Frattini A, Pangrazio A, Susani C, Mirolo M, Abinun M, Andolina M, Flanagan AM, Horwitz EM, Mihci E, Notarangelo LD, Ramenghi U, Teti A, Van Hove J, Young T, Albertini A, Orchard PJ, Vezzoni P, Villa A (2003). Chloride channel C1CN7 mutations are responsible for severe recessive dominant, and intermediate osteopetrosis. Journal of Bone and Mineral Research, 10, 1740 - 1747.
    • Horton MA, Massey HM, Flanagan AM (2003). Upregulation of à2á1 Integrin in á3 null type Glanzmann thrombasthenia enables bone resorption. British Journal of Haematology, 122, 950 - 957.
    • Pratten J, Pasu M, Jackson G, Flanagan A, Wilson M (2003). Modelling oral malodour in a longitudinal study. Archives of Oral Biology, 48(11), 737 - 743.
    • Arnett TR, Massey HM, Utting JC, Orriss IR, Flanagan AM (2003). Hypoxia is a major stimulator of osteoclast formation from human peripheral blood.
    • Flanagan AM, Massey HM (2003). Generating human osteoclasts in vitro from bone marrow and peripheral blood.. Methods in Molecular Medicine, 80, 113 - 128.
    • Macropoulos P, Sieben N, Kolkman-Uljee SM, Al Adani M, Roemen MJM, de Goeij APM, Fleuren J, Diss T, Hamoudi R, Warren B, Krausz T, Flanagan AM, Wellcome Trust Sanger Centre (2003). RAF/RAS mutations in ovarian neoplasms.
    • Flanagan AM, Massey HM (2003). Generating human osteoclasts from bone marrow and peripheral blood. In Helfrich M, Ralston S (Ed.), Bone Research Protocols (pp. 113 - 128). : Humana Press.

    2002

    • Flanagan AM, Massey HM, Wilson C, Vellodi A, Horton MA, Steward CG (2002). Macrophage colony-stimulating factor and rand ligand NF-kB. Bone, 30, 85 - 90.
    • Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosimidou V, Menzies C, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan AM, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seiger HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949 - 954.
    • Kiuru M, Barker K, Launonen V, Lu YJ, Bevan S, Herva R, Arola J, Salovaara R, Jarvinen H, Isola H, Flanagan AM, Wang R, Bridge JA, Fisher C, Shipley J, Delahunt B, Aaltonen LA, Houlston R (2002). Role of the HLRCC/MCUL1 locus in development of leiomyosarcomas and renal cell cancer. British Journal of Cancer, 87, 446 - 448.
    • Lakhani SR, Flanagan AM (2002). Genetics, screening and management. In (Ed.), Pathology of the breat and ovary in mutation carriers in familial breast and ovarian cancer (pp. 108 - 124). : .
    • Barker KT, Bevan S, Wang R, Lu YJ, Flanagan AM, Bridge JA, Fisher C, Finlayson CJ, Shipley J, Houlston RS (2002). Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas.. British Journal of Cancer, 87(4), 446 - 448.
    • Lakhani SR, Flanagan AM (2002). Pathology of the breast and ovary in mutation carriers in familial breast and ovarian cancer. In (Ed.), Familial Breast and Ovarian Cancer: genetics, screening and management (pp. 108 - 124). : CUP.

    2001

    • Rezvani K, Flanagan AM, Sarma U, Constantinovici N, Bain BJ (2001). Investigation of ethnic neutropenia by assessment of bone marrow colony-forming cells.. Acta Haematologica, 105(1), 32 - 37.
    • Sebire NJ, Flanagan AM, Goldin RD (2001). Osseous metaplasia in fetal mesenchyme of the human placenta.
    • Lader CS, Scopes J, Horton MA, Flanagan AM (2001). Generation of human osteoclasts in stromal cell-free and stromal cell- rich cultures: differences in osteoclast CD11c/CD18 integrin expression. British Journal of Haematology, 112(2), 430 - 437.
    • Scopes J, Massey HM, Ebrahim H, Horton MA, Flanagan AM (2001). Interleukin-4 and interleukin-13: bidirectional effects on human osteoclast formation. Bone, 29(3), 203 - 208.
    • Massey HM, Steward CG, Wilson C, Vellodi A, Horton MA, Flanagan AM (2001). Recombinant human RANK ligand (RANKL) and macrophage colony- stimulating factor (M-CSF) fail to rescue human infantile osteoclast-poor osteopetrosis (OP) in vitro. Bone, 28(5), S114 - S114.
    • Massey HM, Horton MA, Flanagan AM (2001). Macrophage-deactivating molecules, transforming growth factor beta(1) (TGF-beta), interleukin (IL)-4 and IL-13 stimulate the osteoclast-forming potential of peripheral blood haemopoietic precursors in a lymphocyte-rich microenvironment. BONE, 28(5), S160 - S160.
    • Horton MA, Seligsohn U, Massey HM, Flanagan AM (2001). Upregulation of alpha 2 beta 1 integrin in beta 3 null type Glanzmann Thrombasthenia enables bone resorption.. J BONE MINER RES, 16, S154 - S154.

    2000

    • Mangion J, Edkins S, Goss AN, Stratton MR, Flanagan AM (2000). Familial craniofacial fibrous dysplasia: absence of linkage to GNAS1 and the gene for cherubism.. Journal of Medical Genetics, 37(11), E37 - .
    • Lloyd J, Flanagan AM (2000). Mammary and extramammary Paget's disease.. Journal of Clinical Pathology, 53(10), 742 - 749.
    • Flanagan AM, Sarma U, Steward CG, Vellodi A, Horton MA (2000). Study of the nonresorptive phenotype of osteoclast-like cells from patients with malignant osteopetrosis: a new approach to investigating pathogenesis. Journal of Bone Mineral Research, 15(2), 352 - 360.

    1999

    • Lader CS, Scopes J, Horton MA, Flanagan AM (1999). Human osteoclasts generated with soluble trance - Differences from stromal-cell based culture systems.. J BONE MINER RES, 14(6), 1033 - 1033.

    1997

    • Lader CS, Horton MA, Flanagan AM (1997). Inhibition of bone resorption by integrin antagonists in human bone-marrow cultures.. J BONE MINER RES, 12, T370 - T370.
    • Lader CS, Horton MA, Flanagan AM (1997). Inhibition of bone resorption by integrin antagonists in human bone-marrow cultures. J BONE MINER RES, 12(9), O3 - O3.

    • Stubbs SA, Hardy K, Da Silva-Buttkus P, Stark J, Webber LJ, Flanagan AM, Themmen AP, Visser JA, Groome NP, Frank S (). Anti-Mullerian Hormone(AMH)protein expression is reduced during the initial stages of follicle development in human polycystic ovaries.. Journal of Clinical Endocrinology and Metabolism, 19, - .
    • Sieben NL, Oosting J, Flanagan AM, Prat J, Roemen GM, Kolkman-Uljee SM, van Eijk R, Cornelisse CJ, Fleuren GJ, Van Engeland M (). Differential gene expression in ovarian tumours reveals dusp4 and serpina 5 as key regulators for benign behavior of serous borderline tumours. Journal of Clinical Oncology, 8, - .
    • Darby AJ, Flanagan AM (). Update on tumour-like lesions of bone.
    • Harish S, Saifuddin A, Cannon SR, Flanagan AM (). Synovial chondromastosis of the foot presenting with Lisfranc dislocation.. Skeletal Radiology, 1, - .